View : 512 Download: 170
The effect of adjuvant chemotherapy on survival in Korean patients with node negative t1c, triple negative breast cancer
- Title
- The effect of adjuvant chemotherapy on survival in Korean patients with node negative t1c, triple negative breast cancer
- Authors
- Lim S.T.; Park C.H.; Kim S.Y.; Nam S.J.; Kang E.Y.; Moon B.-I.; Lee H.J.; Jeon Y.W.; Gwak H.; Suh Y.J.
- Ewha Authors
- 문병인
- SCOPUS Author ID
- 문병인
- Issue Date
- 2018
- Journal Title
- PLoS ONE
- ISSN
- 1932-6203
- Citation
- PLoS ONE vol. 13, no. 5
- Publisher
- Public Library of Science
- Indexed
- SCIE; SCOPUS
- Document Type
- Article
- Abstract
- Background The present study investigated the prognostic role of adjuvant systemic chemotherapy in patients with node negative, T1c triple negative breast cancer (TNBC) from a nationwide cohort. In addition, the prognostic effect between 3 different chemotherapy regimens were compared in node-negative T1c TNBC patients by subgroup analysis. Methods From the Korean breast cancer registry database, 1,151 T1c node negative TNBC patients were included in this study. Patients were categorized into four treatment groups according to chemotherapy regimen: (1) no chemotherapy, (2) adriamycin plus cyclophosphamide (AC), (3) adriamycin/epirubicin plus cyclophosphamide plus 5-FU (FAC/FEC), and (4) cyclophosphamide plus 5-FU plus methotrexate (CMF). Overall survival (OS) was evaluated between each patient group. Results Of the 1,151 T1c node negative TNBC patients, 1,006 received adjuvant chemotherapy, while 145 received no chemotherapy. Among the patients receiving adjuvant chemotherapy the distribution of regimens was: 586 AC, 168 FAC/FEC (126 FAC, 42 FEC), and 252 CMF. The mean follow-up time of the full study cohort was 87.98 ± 33.56 months (range = 6–192 months). Patients in the no chemotherapy group showed significantly worse OS compared to each chemotherapy regimen group. However, when OS was compared between each chemotherapy regimen, no significant difference was found. Conclusions This study showed that adjuvant systemic chemotherapy improved OS in T1c node negative TNBC patients, regardless of chemotherapy between AC, FAC/FEC, and CMF regimens. © 2018 Lim et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
- DOI
- 10.1371/journal.pone.0197523
- Appears in Collections:
- 의과대학 > 의학과 > Journal papers
- Files in This Item:
-
The effect of adjuvant chemotherapy.pdf(891.85 kB)
Download
- Export
- RIS (EndNote)
- XLS (Excel)
- XML